A recent study indicates that patients who stop using blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who end conventional diet and exercise plans.
Published data in a leading medical journal points out that while obese people can lose substantial amounts of their body weight while undergoing treatment, the mass returns at an average rate of nearly a kilo each month after stopping.
"Users purchasing these treatments should be informed of the risk of fast rebound weight gain when the treatment ends," warns lead investigator Dr. Susan Jebb.
This pace of regain means a reversion to original mass in about 18 months.
Comparing Treatments
The study, which looked at dozens of studies involving over 9,000 of patients, contrasted the effects of these new drugs with other pills.
Scientists point out that people who lose weight through dieting generally experience a more gradual weight regain—approximately 100 grams monthly—post-intervention.
Understanding the Rapid Rebound
Nutrition scientists propose the mode of action of the drugs explains the heightened regain.
GLP-1 drugs imitate a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 levels several times higher than normal may cause the system to generate a reduced amount of its own natural hormone, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication leads to appetite is unsuppressed, making overeating a significant risk."
A Lifelong Issue?
The NHS recommend the jabs for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.
Many experts say that, considering the significant potential of relapse, the therapy should be considered ongoing.
This view is reinforced by drug manufacturers, who state that the results "emphasize the persistent nature of excess weight," akin to managing diseases like high blood pressure.
User Experiences
Individuals who have come off the jabs explain a intense return of cravings.
"It was like a switch that goes on and I was suddenly ravenous," recalled a patient.
The struggle is worsened if patients have not developed lasting lifestyle or habit modifications during therapy.
Widespread Adoption
Survey data show that millions of people in the UK have used these injections in the past year, with demand continuing to grow.
- Use is higher among women than men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
In conclusion, clinicians caution that while GLP-1 drugs are potent tools for weight loss, they are not a magic solution and maintained weight loss relies on integrated lifestyle changes.
